Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: A randomized double-blind placebo-controlled study

Pediatric Infectious Disease Journal

Volumn 29, Issue 2, 2010, Pages 105-110

  Englund, Janet A ^a   Walter, Emmanuel ^b   Black, Steven ^c   Blatter, Mark ^d   Nyberg, Jack ^e   Ruben, Frederick L ^e   Decker, Michael D ^e,f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d Primary Physicians Research   (United States)

^e SANOFI PASTEUR   (France)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Childhood vaccines; Immunogenicity; Influenza vaccine; Safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COLIC; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE REACTION; INJECTION SITE SWELLING; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; URTICARIA; VIRUS HEMAGGLUTINATION;

EID: 75949119152     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b84c34     Document Type: Article

References (29)

1. Neuzil KM, Mellen BG, Wright PF. The effect of influenza on hospital-izations, outpatient visits, and antibiotic prescriptions in children. N Engl J Med. 2000;342:225-231.
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospi-talizations in the United States. JAMA. 2004;292:1333-1340.
3. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353:2559-2567.
4. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232-239.
5. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics. 2004;133:585-593.
6. US Department of health and human Services. Guidance on allocating and targeting pandemic influenza vaccine. Available at: www.pandemicflu.gov/ vaccine/allocationguidance.pdf.
7. Ruben F. Inactivated influenza virus vaccines in children. Clin Infect Dis. 2004;38:678-688.
8. Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118:e579-e585.
9. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6-to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006;118:e570-e578.
10. Neuzil KM, Dupont WD, Wright PF, et al. The efficacy of inactivated and cold-adapted vaccines against influenza A infection 1985-1990: the pedi-atric experience. Pediatr Infect Dis J. 2001;20:733-740.
11. Kempe A, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6-to 21-month-old children during the 2003-2004 season. J Pedi-atr. 2006;149:755-762
12. CDC. Surveillance for laboratory-confirmed, influenza-associated hospital-izations-Colorado, 2004-2005 influenza season. MMWR Recomm Rep. 2005; 54:535-537.
13. Groothuis JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months with split product influenza vaccine. Pediatrics. 1991;87:823-828.
14. Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine (TIV) in infants. J Infect Dis. 2008;197:1448-1454.
15. Walter EB, Englund JA, Blatter M, et al. Trivalent inactivated influenza virus vaccines given to 2-month old children: an off-season pilot study. PIDJ. In press.
16. Englund JA, Mbawuike IN, Hammill H, et al. Maternal immunization with influenza or tetanus toxoid vaccine for passive antibody protection in young infants. J Infect Dis. 1993;168:647-656.
17. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal immunization in mothers and infants. N Engl J Med. 2008;350:1555-1564.
18. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendation of the Advisory Committee on Immunmization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1-60.
19. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2005;192:1098-1106.
20. Englund JA. Maternal immunization with inactivated influenza vaccine: rationale and experience. Vaccine. 2003;21:3460-3464.
21. CDC. Weekly report: influenza summary update, May 2006. www.cdc.gov/ flu/weekly/weeklyarchives2005-2006/weekly20.htm, Accessed May 18, 2009.
22. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J. 2000;19:1045-1052.
23. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96:580-584.
24. Englund JA, Glezen WP, Thompson C, et al. Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr Infect Dis J. 1997;16:1122-1130.
25. Johnson CE, Nalin DR, Chui LW, et al. Measles vaccine immunogenicity in 6-versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics. 1994;93:939-944.
26. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenic-ity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194:1032-1039.
27. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine. 2007; 25:7656-7663.
28. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-10):1-42.
29. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001;154:155-160.